# A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

> **NCT02691975** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 197 (actual)

## Conditions studied

- Hormone Refractory Prostate Cancer
- Metastatic Prostate Carcinoma

## Interventions

- **DRUG:** SHR3680

## Key facts

- **NCT ID:** NCT02691975
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04-12
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2020-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02691975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02691975, "A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02691975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*